Why extractables and leachables (E&L) matter in stability:

Extractables are compounds that can be released from packaging materials under aggressive conditions, while leachables are those that migrate into the product under actual storage conditions. When left unchecked, these compounds can compromise drug purity, potency, and safety. E&L testing during stability ensures the container-closure system does not negatively impact product quality over time.

When is E&L testing required during stability?

E&L testing becomes essential when the product is a biologic, parenteral, inhalation drug, or uses novel packaging materials like multi-layered plastics or rubber stoppers. It’s also necessary if degradation trends suggest chemical migration, or if prior extractables studies identified high-risk substances. Failure to include E&L when indicated may result in regulatory queries or delayed approval.

Regulatory and Technical Context:

ICH Q3E and global regulatory expectations:

ICH Q3E specifically addresses the need for leachable testing when a risk of interaction exists. US FDA, EMA, Health Canada, and WHO TRS 1010 emphasize container-closure system integrity and its effect on product stability. CTD Module 3.2.P.7 must describe the packaging and any relevant E&L data. Leachables are often tracked as part of long-term and accelerated stability to assess cumulative impact over time.

Audit readiness and submission significance:

During inspections, regulators expect evidence that leachable risks have been considered. If data is missing or if leachable spikes are observed without explanation, the product may face shelf-life limitations or post-approval testing requirements. Submissions should include E&L summaries in Modules 3.2.P.5.5 and 3.2.P.8.3, especially for high-risk dosage forms.

Best Practices and Implementation:

Conduct extractables studies before initiating stability:

Perform a thorough extractables study using aggressive solvents and elevated conditions to identify potential leachable candidates from packaging materials. Use multiple analytical techniques (e.g., GC-MS, LC-MS, ICP-MS) and maintain a database of compounds with chemical identities, retention times, and toxicological thresholds.

This data forms the basis for targeted leachables monitoring during stability.

Integrate leachables testing into your stability protocol:

Include specific test parameters in the protocol for high-risk time points (e.g., 6, 12, 24 months) or storage conditions (e.g., 40°C/75% RH). Monitor for known leachables using validated methods with sensitivity below the safety thresholds. Define action limits, reporting levels, and OOS criteria in alignment with toxicological risk assessments (e.g., TTC or PDE).

Apply bracketing strategies where packaging material variants are used and ensure that test frequency is justified in the protocol.

Document results clearly and act on findings:

Include E&L results in the final stability reports and trend them alongside physical, chemical, and microbial attributes. Highlight any upward trends, correlate with extractables profile, and initiate risk assessments if thresholds are breached. Use these insights to adjust packaging, revise specifications, or initiate toxicological reviews as needed.

Maintain traceability between E&L results, stability conditions, and packaging lots in both regulatory submissions and internal audits.

Why packaging clarity matters in stability studies:

During development, it’s common to initiate stability studies using interim packaging while final commercial packaging is still under design, validation, or procurement. However, the barrier properties, closure integrity, material interaction, and container size can differ significantly. Without clearly documenting the distinction, stability data may be misused or misinterpreted in regulatory submissions or internal decision-making.

Risks of ignoring packaging differences:

Data generated from interim packs may not represent real-world storage behavior, leading to incorrect shelf-life claims or inadequate risk controls. Regulatory authorities may question the relevance of such data, especially if the final container is less protective than the interim version. In some cases, approval delays or shelf-life reductions may occur due to lack of clear justification.

Regulatory and Technical Context:

ICH and GMP expectations for packaging traceability:

ICH Q1A(R2) and WHO TRS 1010 require that stability data reflect the final marketed container-closure system or a scientifically justified surrogate. Module 3.2.P.7 of the CTD must specify the packaging used in studies and how it correlates with the commercial pack. GMP expectations also include traceability of packaging lot numbers, material grade, and closure specifications throughout the study lifecycle.

What inspectors and regulators evaluate:

Auditors and regulatory reviewers often cross-check packaging details in the stability summary, reports, and protocol appendices. Inconsistencies—such as missing justification for using a different cap, vial, or blister material—can trigger deficiencies or supplemental data requests. Agencies may also review whether extrapolated shelf life was based on relevant container systems.

Best Practices and Implementation:

Clearly define packaging used at each study phase:

Document all packaging configurations (interim, final, clinical trial, exhibit batch) used across batches and time points. Include detailed specifications such as:

• Primary container material (e.g., Type I glass, HDPE)
• Closure components (e.g., rubber stopper type, induction seal)
• Secondary packaging (e.g., cartons, inserts, desiccants)

Indicate in the protocol whether the packaging is interim or final and justify its use based on material equivalence or historical performance.

Evaluate comparative studies where needed:

If switching from interim to final packaging mid-study, consider conducting side-by-side comparative stability studies at key conditions (e.g., 25°C/60% RH, 30°C/75% RH). Analyze assay, impurity, moisture, and appearance trends to ensure performance equivalence. Where significant differences exist, document them and adjust shelf-life justification accordingly.

Include these studies in CTD Module 3.2.P.8.3 and reference findings in labeling discussions or product lifecycle strategies.

Link packaging status to labeling and submission documentation:

Ensure your CTD accurately reflects the packaging used in stability data presented in Modules 3.2.P.7 and 3.2.P.8. Include a summary table linking each batch to its packaging configuration, time points, and justification. If interim data is used for initial approval, commit to bridging studies or updating the data with final packs in post-approval variations.

Maintain transparency in regulatory submissions and inspection readiness materials to minimize objections and demonstrate proactive stability management.

Why container-closure systems matter:

Stability testing simulates how a drug product will behave over its shelf life. If the container-closure system used during testing doesn’t match the one used in the market, the results may not reflect real-world conditions.

Packaging directly impacts exposure to moisture, oxygen, and light—all of which influence chemical and physical stability. Therefore, using the final packaging system is essential for generating valid, defensible data.

Risks of mismatched testing conditions:

Testing in an alternative or interim container—such as clear vials, bulk HDPE bottles, or temporary seals—can underestimate degradation or fail to detect vulnerabilities that would arise in the actual distribution environment.

This mismatch could lead to label inaccuracies, recall risk, or regulatory rejection due to data that doesn’t match commercial conditions.

Regulatory implications of incorrect simulation:

Authorities like the FDA, EMA, and CDSCO expect that the container-closure used during stability studies mirrors the proposed commercial presentation. Deviations must be scientifically justified and rarely accepted.

Ensuring a match helps streamline regulatory approval and builds trust in the reliability of submitted shelf life claims.

Regulatory and Technical Context:

ICH Q1A(R2) requirements:

The ICH guideline explicitly mandates that stability testing be conducted using the same container-closure system proposed for marketing. This ensures the impact of packaging on product stability is fully evaluated before commercialization.

It also requires consideration of closure integrity, extractables/leachables, and the effect of packaging materials under intended storage conditions.

Container types and their stability impact:

Glass vs. plastic, screw caps vs. induction seals, blister foils vs. clear PVC—all have varying barrier properties. Each can alter moisture vapor transmission rates (MVTR), gas permeability, and light exposure.

Neglecting to use final packaging may lead to shelf life that is either overestimated or unnecessarily short, affecting product competitiveness and patient safety.

Packaging data in regulatory submissions:

Container-closure details are submitted in Module 3.2.P.7 of the CTD. Reviewers examine whether the data generated applies to the final market configuration, and if not, require bridging studies or label restrictions.

Proper testing from the start reduces back-and-forth during review and supports efficient global rollout.

Best Practices and Implementation:

Align study protocol with packaging components:

Ensure your stability protocol clearly specifies the container-closure system used for each batch. Match this to commercial packaging in terms of material, volume, and closure design.

If early batches are tested in development packaging, plan for bridging studies and outline the rationale in your protocol and submission.

Include packaging in validation and qualification plans:

Validate the packaging line and confirm it meets closure integrity requirements before stability sample preparation. Conduct visual inspections, torque tests, and leak tests to ensure packaging consistency.

Use packaging suppliers with traceable documentation and materials that meet USP, EP, or JP standards.

Account for packaging in shelf-life justification:

Include data demonstrating that the packaging supports the proposed storage conditions (e.g., light protection, moisture control). This supports shelf-life projections and labeling statements like “Store in a tightly closed container” or “Protect from light.”

Regulatory authorities may request packaging-specific stability data in post-approval variations—prepare for this in advance by maintaining a well-structured study archive.

Stability testing is a vital component of ensuring the quality, safety, and efficacy of pharmaceutical products. The purpose of stability testing is multi-faceted and serves as a critical safeguard in pharmaceutical manufacturing. Let’s explore the significance of stability testing in the pharmaceutical industry: